Group 1: Company Overview - Tianjin Jiuan Medical Electronics Co., Ltd. (referred to as "Jiuan Medical") held an investor online communication meeting on January 28, 2026, discussing product development, diabetes care "O+O" new model, AIoT diabetes home assistant project, sci-tech investment, and shareholder return planning [1] Group 2: IVD Product Progress - Jiuan Medical's IVD product, the iHealth four-in-one test kit, received FDA 510(k) pre-market notification in December 2025 and is now available for sale at CVS and on Amazon, priced at $29.99 for two tests and $49.99 for four tests [2] - The product expands the range of detectable viruses, meeting diverse respiratory virus screening needs in the U.S. market, enhancing core competitiveness [2] Group 3: Diabetes Care "O+O" New Model - The "O+O" model focuses on comprehensive diabetes management, with partnerships established in 424 hospitals across approximately 50 cities in China, managing over 366,000 patients [3] - The model has improved the glycated hemoglobin target rate from around 30% to 60%, with adverse event rates dropping below 5% and management rates increasing to 70% [3] - In the U.S., collaborations with about 74 clinics and 394 doctors are managing approximately 21,000 patients [3] Group 4: AIoT Diabetes Home Assistant - The AIoT diabetes home assistant project aims to develop an intelligent, personalized chronic disease management tool using advanced AI technology, with a complete AI module expected to launch in Q2 2026 [4] - The system is designed to enhance the efficiency of caregivers rather than replace them, utilizing a specialized AI model trained on health data from 366,000 diabetes patients [4] Group 5: Sci-Tech Investment - Since 2022, Jiuan Medical has committed over 4.3 billion yuan to various investment fields, including hard technology, healthcare, AI, and new materials, through partnerships with 27 venture capital funds [5][6] - The focus is on next-generation AI technologies and their applications, aiming for comprehensive coverage of the AI industry chain [6] Group 6: Shareholder Return Planning - Jiuan Medical has canceled 29,954,222 shares of treasury stock and plans to distribute cash dividends amounting to no less than 30% of cumulative net profits over the next three years [7] - The company aims to maintain market value and enhance stock price reflection of intrinsic value through strategic stock repurchases and improved business performance [7]

Core Viewpoint - The issuance of the technology innovation bonds by Jiuan Medical was successful, achieving an AAA credit rating and a 1.83% issuance interest rate, with an initial issuance scale of 1.05 billion yuan, reflecting market trust and recognition of the company's development [1]. Group 1: Company Overview - Jiuan Medical is primarily known for producing common household health monitoring devices such as thermometers, blood pressure monitors, and pulse oximeters, but it has diversified into home medical health products, internet healthcare, and technology investment [1]. - The company plans to invest approximately 270 million yuan in research and development in 2024, focusing on projects like continuous glucose monitoring (CGM) and AIoT diabetes home assistance [1]. Group 2: Bond Issuance Process - The company faced initial challenges in the bond issuance process, particularly regarding credit rating, but successfully communicated with rating agencies to demonstrate asset quality and financial health, ultimately achieving an AAA rating [2][3]. - The technology innovation bonds are designed to meet the financing needs of technology companies, allowing funds to be used for R&D, direct investments, and fund contributions, thereby enhancing capital turnover efficiency and reducing overall financing costs [2]. Group 3: Market Context and Challenges - Jiuan Medical's financial indicators met the requirements for issuing technology innovation bonds, and its intellectual property, including FDA approval, was considered a significant asset in the evaluation process [3]. - The company expressed concerns about the bond market's unfamiliarity, including questions about the efficiency of the issuance process and the potential for successful fundraising, which were addressed in a policy briefing organized by the China Interbank Market Dealers Association [3]. Group 4: Industry Implications - The issuance of technology innovation bonds is expected to inject new momentum into Jiuan Medical and its associated funds, accelerating the transformation of quality projects and technological achievements [4]. - The current challenge for many technology innovation companies is their asset-light operating model, which often lacks public market ratings, limiting support from traditional financing channels [4][5].